Preparation and in vitro evaluation of pyridostigmine bromide microparticles.
Pyridostigmine bromide (PB) is an anticholinesterase agent whose aqueous solubility is high and which has a short elimination half-life. Its dosage rate in the treatment of myastenia gravis is frequent due to the short half-life and it exhibits side effects. Microparticles designed to deliver a pharmaceutical active ingredient efficiently at the minimum dose and also to enhance stability, reduce side effects and modify drug release were prepared in this study using an acrylic polymer (Eudragit) as the vehicle by the spray-drying technique. The drug was either dissolved or dispersed in the polymeric solution and following the preparation of microparticles using different ratios of ingredients, characterization studies including the determination of shape, particle size distribution, amount loaded, release and stability of PB were performed. The results obtained were compared to those of pure PB. Drug release from microparticles could be modified and was found to depend on the shapes of the microparticles. In vitro evaluation results indicate that the frequent dosage and side effects of pure PB may be reduced with the formulation of microparticles.
Hegazy
Nahed
N
Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, 26470, Eskişehir, Turkey.
Demirel
Müzeyyen
M
Yazan
Yasemin
Y
D000180:Acrylic Resins; D002214:Capsules; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000737:chemistry; D018360:Crystallography, X-Ray; D005079:Excipients; D006207:Half-Life; D010316:Particle Size; D011208:Powders; D011729:Pyridostigmine Bromide / Q000008:administration & dosage* / Q000737:chemistry; D013055:Spectrophotometry, Infrared
D000180:Acrylic Resins; D002214:Capsules; D002800:Cholinesterase Inhibitors; D005079:Excipients; D011208:Powders; C050528:Eudragit RS; D011729:Pyridostigmine Bromide